| Amy Lockwood, CRNA | |
|
632 N 12th St # 230, Murray, KY 42071-1651 | |
| (270) 705-9065 | |
| Not Available |
| Full Name | Amy Lockwood |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 14 Years |
| Location | 632 N 12th St # 230, Murray, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497051957 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 3006815 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Murray-calloway County Hospital | Murray, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Murray Anesthetists Group, Pllc | 6709057854 | 15 |
News Archive
University of California San Diego School of Medicine researchers found evidence that triclosan - an antimicrobial found in many soaps and other household items - worsens fatty liver disease in mice fed a high-fat diet.
Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms.
Ankle muscle strength and joint mobility are the key factors influencing gait abnormalities in people with diabetic peripheral neuropathy, Brazilian research suggests.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 1 days ago
| Entity Name | Trigg County Hospital, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538218680 PECOS PAC ID: 5193620805 Enrollment ID: O20031205000118 |
News Archive
University of California San Diego School of Medicine researchers found evidence that triclosan - an antimicrobial found in many soaps and other household items - worsens fatty liver disease in mice fed a high-fat diet.
Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms.
Ankle muscle strength and joint mobility are the key factors influencing gait abnormalities in people with diabetic peripheral neuropathy, Brazilian research suggests.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 1 days ago
| Entity Name | Trigg County Hospital, Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538218680 PECOS PAC ID: 5193620805 Enrollment ID: O20080103000025 |
News Archive
University of California San Diego School of Medicine researchers found evidence that triclosan - an antimicrobial found in many soaps and other household items - worsens fatty liver disease in mice fed a high-fat diet.
Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms.
Ankle muscle strength and joint mobility are the key factors influencing gait abnormalities in people with diabetic peripheral neuropathy, Brazilian research suggests.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 1 days ago
| Entity Name | Murray Anesthetists Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164701447 PECOS PAC ID: 6709057854 Enrollment ID: O20110921000110 |
News Archive
University of California San Diego School of Medicine researchers found evidence that triclosan - an antimicrobial found in many soaps and other household items - worsens fatty liver disease in mice fed a high-fat diet.
Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms.
Ankle muscle strength and joint mobility are the key factors influencing gait abnormalities in people with diabetic peripheral neuropathy, Brazilian research suggests.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Lockwood, CRNA 632 N 12th St # 230, Murray, KY 42071-1651 Ph: (270) 705-9065 | Amy Lockwood, CRNA 632 N 12th St # 230, Murray, KY 42071-1651 Ph: (270) 705-9065 |
News Archive
University of California San Diego School of Medicine researchers found evidence that triclosan - an antimicrobial found in many soaps and other household items - worsens fatty liver disease in mice fed a high-fat diet.
Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms.
Ankle muscle strength and joint mobility are the key factors influencing gait abnormalities in people with diabetic peripheral neuropathy, Brazilian research suggests.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 1 days ago
Edward S Parrish Iii, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 803 Poplar St, Murray, KY 42071 Phone: 270-762-1100 | |
Mr. Adam Shane David, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 632 N 12th St # 230, Murray, KY 42071 Phone: 859-948-8389 | |
Margaret L. Daniel, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 632 N 12th St # 230, Murray, KY 42071 Phone: 831-431-3243 | |
Ashley Jane Young, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 632 N 12th St # 230, Suite 400, Murray, KY 42071 Phone: 270-293-9637 | |
Jennifer A Green, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 632 N 12th St # 230, Murray, KY 42071 Phone: 270-748-6851 | |
Maria D Jennings, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 632 N 12th St # 230, Murray, KY 42071 Phone: 270-227-6405 |